Unknown

Dataset Information

0

Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists.

ABSTRACT: Takeda G-protein-coupled receptor 5 (TGR5) is emerging as an important and promising target for the development of anti-diabetic drugs. To understand the structural characteristics of TGR5 agonists, the common feature pharmacophore models were generated and molecular docking was performed. The ligand-based virtual screening combined with pharmacophore mapping and molecular docking was performed to identify novel nonsteroidal TGR5 agonists. Finally, 20 compounds were screened for in vitro TGR5 agonistic activity assay, and results showed most compounds exhibiting TGR5 agonistic activity at 40 μM. Among these compounds, V12 and V14 displayed obvious TGR5 agonist activity, with the EC50 values of 19.5 μM and 7.7 μM, respectively. Compounds V12 and V14 could be considered potential TGR5 agonist candidates and also may be used as initial hits for developing novel TGR5 agonists.

SUBMITTER: Zhao S 

PROVIDER: S-EPMC8695346 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists.

Zhao Shizhen S   Li Xinping X   Peng Wenjing W   Wang Le L   Ye Wenling W   Zhao Yang Y   Yin Wenbo W   Chen Wei-Dong WD   Li Weiguo W   Wang Yan-Dong YD  

RSC advances 20210302 16

Takeda G-protein-coupled receptor 5 (TGR5) is emerging as an important and promising target for the development of anti-diabetic drugs. To understand the structural characteristics of TGR5 agonists, the common feature pharmacophore models were generated and molecular docking was performed. The ligand-based virtual screening combined with pharmacophore mapping and molecular docking was performed to identify novel nonsteroidal TGR5 agonists. Finally, 20 compounds were screened for <i>in vitro</i>  ...[more]

Similar Datasets

Unknown Pharmacophore-guided Virtual Screening to Identify New β<sub>3</sub> -adrenergic Receptor Agonists.
| S-EPMC9400856 | biostudies-literature
Unknown Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors.
| S-EPMC4265523 | biostudies-literature
Unknown Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists.
| S-EPMC8693749 | biostudies-literature
Unknown Discovery of new liver X receptor agonists by pharmacophore modeling and shape-based virtual screening.
| S-EPMC3934620 | biostudies-literature
Unknown Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies.
| S-EPMC9042709 | biostudies-literature
Unknown Targeting Dengue Virus NS-3 Helicase by Ligand based Pharmacophore Modeling and Structure based Virtual Screening.
| S-EPMC5671650 | biostudies-literature
Unknown Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.
| S-EPMC4088285 | biostudies-literature
Unknown Pharmacophore Based Virtual Screening Approach to Identify Selective PDE4B Inhibitors.
| S-EPMC5610747 | biostudies-literature
Unknown Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.
| S-EPMC4150255 | biostudies-literature
Unknown Ligand-based Pharmacophore Modeling, Virtual Screening and Molecular Docking Studies for Discovery of Potential Topoisomerase I Inhibitors.
| S-EPMC6396084 | biostudies-literature